

# Florian M E Wagenlehner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3788558/publications.pdf>

Version: 2024-02-01

175  
papers

6,246  
citations

66343

42  
h-index

88630

70  
g-index

196  
all docs

196  
docs citations

196  
times ranked

5728  
citing authors

#	ARTICLE	IF	CITATIONS
1	The efficacy and tolerability of pollen extract in combination with hyaluronic acid and vitamins in the management of patients affected by chronic prostatitis/chronic pelvic pain syndrome: a 26 weeks, randomized, controlled, single-blinded, phase III study. <i>Minerva Urology and Nephrology</i> , 2023, 74, .	2.5	5
2	Management of uncomplicated recurrent urinary tract infections. <i>BJU International</i> , 2022, 129, 668-678.	2.5	15
3	Re: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. <i>European Urology</i> , 2022, 81, 213.	1.9	6
4	A global perspective on improving patient care in uncomplicated urinary tract infection: expert consensus and practical guidance. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 28, 18-29.	2.2	18
5	Comparative Analysis of Guideline Adherence between Germany and Austria by Using the Example of Uncomplicated Urinary Tract Infections. <i>Urologia Internationalis</i> , 2022, 106, 1018-1024.	1.3	2
6	Management of Recurrent Cystitis in Women: When Prompt Identification of Risk Factors Might Make a Difference. <i>European Urology Focus</i> , 2022, 8, 1476-1482.	3.1	5
7	Translation and validation of the Korean version of acute cystitis symptom score. <i>Investigative and Clinical Urology</i> , 2022, 63, 221.	2.0	2
8	Why d-Mannose May Be as Efficient as Antibiotics in the Treatment of Acute Uncomplicated Lower Urinary Tract Infectionsâ€”Preliminary Considerations and Conclusions from a Non-Interventional Study. <i>Antibiotics</i> , 2022, 11, 314.	3.7	8
9	The Management of Urinary Tract Infections during the COVID-19 Pandemic: What Do We Need to Know?. <i>Uro</i> , 2022, 2, 55-64.	0.8	3
10	Comparison of Urine Flow Cytometry on the UF-1000i System and Urine Culture of Urine Samples from Urological Patients. <i>Urologia Internationalis</i> , 2022, 106, 858-868.	1.3	1
11	Psychosocial burden of recurrent uncomplicated urinary tract infections.. <i>GMS Infectious Diseases</i> , 2022, 10, Doc01.	0.8	10
12	Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1558-1566.	6.0	11
13	Hyperbaric Oxygenation in the Treatment of Fournierâ€™s Gangrene: A Systematic Review. <i>Urologia Internationalis</i> , 2021, 105, 247-256.	1.3	14
14	Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVIDâ€“19) pandemic: an international accelerated consensus statement. <i>BJU International</i> , 2021, 127, 729-741.	2.5	9
15	European Association of Urology Position Paper on the Prevention of Infectious Complications Following Prostate Biopsy. <i>European Urology</i> , 2021, 79, 11-15.	1.9	41
16	Anti-Biofilm Effect of Octenidine and Polyhexanide on Uropathogenic Biofilm-Producing Bacteria. <i>Urologia Internationalis</i> , 2021, 105, 278-284.	1.3	10
17	The negative aftermath of prostate biopsy: prophylaxis, complications and antimicrobial stewardship: results of the global prevalence study of infections in urology 2010â€“2019. <i>World Journal of Urology</i> , 2021, 39, 3423-3432.	2.2	15
18	Sexual Health in HIV-Positive Men Under Stable Antiretroviral Therapy During a 12-Month Period. <i>Journal of Sexual Medicine</i> , 2021, 18, 284-294.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Management of penile cancer patients during the COVID-19 pandemic: An eUROGEN accelerated Delphi consensus study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 197.e9-197.e17.	1.6	9
20	Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2021, 205, 653-663.	0.4	79
21	Epidemiological study of the prevalence of cystitis in women of the Voronezh region. <i>Experimental and Clinical Urology</i> , 2021, 14, 10-18.	0.3	0
22	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 832-832.	0.4	0
23	Epidemiology and O-Serotypes of Extraintestinal Pathogenic <i>Escherichia coli</i> Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study. <i>Journal of Urology</i> , 2021, 205, 826-832.	0.4	5
24	Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. <i>Clinical Microbiology and Infection</i> , 2021, 27, 671-686.	6.0	54
25	Physiological and pharmacological impact of oxytocin on epididymal propulsion during the ejaculatory process in rodents and men. <i>FASEB Journal</i> , 2021, 35, e21639.	0.5	3
26	Linguistic and clinical validation of the acute cystitis symptom score in German-speaking Swiss women with acute cystitis. <i>International Urogynecology Journal</i> , 2021, 32, 3275-3286.	1.4	2
27	Treatment of Urinary Tract Infections with Canephron® in Germany: A Retrospective Database Analysis. <i>Antibiotics</i> , 2021, 10, 685.	3.7	16
28	Chronic Prostatitis/Chronic Pelvic Pain Syndrome Leads to Impaired Semen Parameters, Increased Sperm DNA Fragmentation and Unfavorable Changes of Sperm Protamine mRNA Ratio. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7854.	4.1	9
29	Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2399-2414.	4.0	15
30	Clinical Validation of the Greek Version of the Acute Cystitis Symptom Score (ACSS) – Part II. <i>Antibiotics</i> , 2021, 10, 1253.	3.7	3
31	Natural Bred $\mu$ 2-Phages Have an Improved Host Range and Virulence against Uropathogenic <i>Escherichia coli</i> over Their Ancestor Phages. <i>Antibiotics</i> , 2021, 10, 1337.	3.7	6
32	Antibiotic resistance, hospitalizations, and mortality related to prostate biopsy: first report from the Norwegian Patient Registry. <i>World Journal of Urology</i> , 2020, 38, 17-26.	2.2	43
33	Metagenomics in diagnosis and improved targeted treatment of UTI. <i>World Journal of Urology</i> , 2020, 38, 35-43.	2.2	13
34	Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women. <i>World Journal of Urology</i> , 2020, 38, 63-72.	2.2	20
35	Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study. <i>World Journal of Urology</i> , 2020, 38, 27-34.	2.2	10
36	Additional assessment of Acute Cystitis Symptom Score questionnaire for patient-reported outcome measure in female patients with acute uncomplicated cystitis: part II. <i>World Journal of Urology</i> , 2020, 38, 1977-1988.	2.2	18

#	ARTICLE	IF	CITATIONS
37	Associated measures to antibiotic prophylaxis in urology. <i>World Journal of Urology</i> , 2020, 38, 9-15.	2.2	3
38	Recent research in urological infections. <i>Nature Reviews Urology</i> , 2020, 17, 65-66.	3.8	2
39	Urogenital infections. <i>World Journal of Urology</i> , 2020, 38, 1-2.	2.2	14
40	Increase of leucocyte-derived extracellular traps (ETs) in semen samples from human acute epididymitis patients—a pilot study. <i>Journal of Assisted Reproduction and Genetics</i> , 2020, 37, 2223-2231.	2.5	14
41	<i>Escherichia coli</i> Resistance to Fluoroquinolones in Community-Acquired Uncomplicated Urinary Tract Infection in Women: a Systematic Review. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	44
42	Epidemiology, definition and treatment of complicated urinary tract infections. <i>Nature Reviews Urology</i> , 2020, 17, 586-600.	3.8	132
43	Validation of the American English Acute Cystitis Symptom Score. <i>Antibiotics</i> , 2020, 9, 929.	3.7	10
44	Acute Cystitis Symptom Score (ACSS): Clinical Validation of the Italian Version. <i>Antibiotics</i> , 2020, 9, 104.	3.7	17
45	The Clinical Application and Potential Roles of Circulating Tumor Cells in Bladder Cancer and Prostate Cancer. <i>Urology</i> , 2020, 145, 30-37.	1.0	2
46	Anti-Bacterial Effects of Essential Oils against Uropathogenic Bacteria. <i>Antibiotics</i> , 2020, 9, 358.	3.7	9
47	“TREXIT 2020” why the time to abandon transrectal prostate biopsy starts now. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 62-65.	3.9	68
48	Guidelines in urology: Lights and shadows. <i>Urologia</i> , 2020, 87, 125-129.	0.7	4
49	Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 204, 224-230.	0.4	85
50	Acute Cystitis Symptom Score questionnaire for measuring patient-reported outcomes in women with acute uncomplicated cystitis: Clinical validation as part of a phase III trial comparing antibiotic and nonantibiotic therapy. <i>Investigative and Clinical Urology</i> , 2020, 61, 498.	2.0	7
51	Editorial Comment. <i>Journal of Urology</i> , 2020, 203, 577-578.	0.4	0
52	Calculated parenteral initial treatment of bacterial infections: Infections of the kidneys and the genito-urinary tract. <i>GMS Infectious Diseases</i> , 2020, 8, Doc12.	0.8	0
53	Re: COVID-19 Coagulopathy: Considerations for Urologists. <i>Journal of Urology</i> , 2020, 204, 848-849.	0.4	1
54	Determination of leucocyte extracellular traps (ETs) in seminal fluid (ex vivo) in infertile patients—a pilot study. <i>Andrologia</i> , 2019, 51, e13356.	2.1	13

#	ARTICLE	IF	CITATIONS
55	Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	5
56	High prevalence of urogenital infection/inflammation in patients with azoospermia does not impede surgical sperm retrieval. <i>Andrologia</i> , 2019, 51, e13401.	2.1	15
57	Update on Strategies to Reduce Infectious Complications After Prostate Biopsy. <i>European Urology Focus</i> , 2019, 5, 20-28.	3.1	33
58	Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 633-641.	2.5	13
59	Monocyte-derived extracellular trap (MET) formation induces aggregation and affects motility of human spermatozoa in vitro. <i>Systems Biology in Reproductive Medicine</i> , 2019, 65, 357-366.	2.1	21
60	Time to Adapt Our Practice? The European Commission Has Restricted the Use of Fluoroquinolones since March 2019. <i>European Urology</i> , 2019, 76, 273-275.	1.9	42
61	Urinary bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant <i>Escherichia coli</i> . <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 55-61.	2.5	10
62	Appropriate empiric antibiotic choices in health care associated urinary tract infections in urology departments in Europe from 2006 to 2015: A Bayesian analytical approach applied in a surveillance study. <i>PLoS ONE</i> , 2019, 14, e0214710.	2.5	20
63	Once-Daily Plazomicin for Complicated Urinary Tract Infections. <i>New England Journal of Medicine</i> , 2019, 380, 729-740.	27.0	159
64	Understanding clinical variables to improve empirical antibiotic therapy for UTI. <i>Nature Reviews Urology</i> , 2019, 16, 695-696.	3.8	1
65	Management of Urethritis: Is It Still the Time for Empirical Antibiotic Treatments?. <i>European Urology Focus</i> , 2019, 5, 29-35.	3.1	13
66	Management of Urosepsis in 2018. <i>European Urology Focus</i> , 2019, 5, 5-9.	3.1	49
67	Novel Antibiotics in the Treatment of Urinary Tract Infections. <i>European Urology Focus</i> , 2019, 5, 10-12.	3.1	9
68	Reliability of Symptom-Based Diagnosis of Uncomplicated Cystitis. <i>Urologia Internationalis</i> , 2019, 102, 83-95.	1.3	21
69	In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default?. <i>European Urology</i> , 2019, 75, 205-207.	1.9	13
70	Cefiderocol for treatment of complicated urinary tract infections. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 22-23.	9.1	9
71	Transurethral Resection of the Prostate: are We Following the Guidelines? - Outcomes from the Global Prevalence of Infections in Urology (GPIU) Study. <i>Journal of Chemotherapy</i> , 2019, 31, 15-22.	1.5	6
72	Awareness and perception of multidrug-resistant organisms and antimicrobial therapy among internists vs. surgeons of different specialties: Results from the German MR2 Survey. <i>Caspian Journal of Internal Medicine</i> , 2019, 10, 132-141.	0.2	4

#	ARTICLE	IF	CITATIONS
73	Expression of terminal deoxynucleotidyl transferase (TdT) in classical seminoma: a potential diagnostic pitfall. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 433-440.	2.8	7
74	Re: Letter to the editor. <i>International Urology and Nephrology</i> , 2018, 50, 875-875.	1.4	0
75	The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients: Part I. <i>Urologia Internationalis</i> , 2018, 100, 263-270.	1.3	58
76	Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 422-426.	2.5	7
77	Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. <i>World Journal of Urology</i> , 2018, 36, 323-330.	2.2	38
78	Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-Year results of the Global Prevalence Study of Infections in Urology (GPIU). <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 278-283.	1.7	29
79	Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study. <i>Urologia Internationalis</i> , 2018, 101, 16-24.	1.3	28
80	The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. <i>Urologia Internationalis</i> , 2018, 100, 271-278.	1.3	80
81	Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT). <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 107-117.	1.4	96
82	Novel imaging of the prostate reveals spontaneous gland contraction and excretory duct quiescence together with different drug effects. <i>FASEB Journal</i> , 2018, 32, 1130-1138.	0.5	6
83	Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. <i>Urologia Internationalis</i> , 2018, 101, 327-336.	1.3	81
84	Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part I. Development, Diagnosis and Differential Diagnosis. <i>Antibiotics</i> , 2018, 7, 6.	3.7	18
85	Preventing urinary tract infections in patients with neurogenic bladder. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 926-927.	9.1	2
86	Treatment Options for Carbapenem-Resistant Gram-Negative Infections. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2018, 115, 345-352.	0.9	68
87	Re: Acute Pyelonephritis in Adults. <i>European Urology</i> , 2018, 74, 676.	1.9	0
88	Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part II. Patient-Reported Outcome Assessment. <i>Antibiotics</i> , 2018, 7, 43.	3.7	15
89	Response to "Aberrant expression of TdT in seminomatous germ cell neoplasia"™. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 387-387.	2.8	1
90	Serum bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant <i>Escherichia coli</i> . <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 783-789.	2.5	20

#	ARTICLE	IF	CITATIONS
91	Elevated seminal plasma estradiol and epigenetic inactivation of ESR1 and ESR2 is associated with CP/CPPS. <i>Oncotarget</i> , 2018, 9, 19623-19639.	1.8	10
92	The role of the Acute Cystitis Symptom Score questionnaire for research and antimicrobial stewardship. Validation of the Hungarian version. <i>Central European Journal of Urology</i> , 2018, 71, 134-141.	0.3	11
93	Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw486.	3.0	17
94	A new way to prevent urinary tract infections?. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 467-468.	9.1	4
95	Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial. <i>Urology</i> , 2017, 103, 191-197.	1.0	43
96	Impact of the medical specialty on knowledge regarding multidrug-resistant organisms and strategies toward antimicrobial stewardship. <i>International Urology and Nephrology</i> , 2017, 49, 1311-1318.	1.4	24
97	How the microbiome is influenced by the therapy of urological diseases: standard versus alternative approaches. <i>Clinical Phytoscience</i> , 2017, 3, .	1.6	9
98	An update on classification and management of urosepsis. <i>Current Opinion in Urology</i> , 2017, 27, 133-137.	1.8	47
99	Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2017, 58, 96-109.	3.3	19
100	Ceftazidime+avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections. <i>Future Microbiology</i> , 2017, 12, 655-670.	2.0	4
101	Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. <i>Urology</i> , 2017, 104, 11-21.	1.0	92
102	Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. <i>European Urology</i> , 2017, 72, 865-868.	1.9	89
103	Editorial Comment. <i>Journal of Urology</i> , 2017, 198, 114-115.	0.4	0
104	Chronic Prostatitis Affects Male Reproductive Health and Is Associated with Systemic and Local Epigenetic Inactivation of C-X-C Motif Chemokine 12 Receptor C-X-C Chemokine Receptor Type 4. <i>Urologia Internationalis</i> , 2017, 98, 89-101.	1.3	18
105	Is Preoperative Assessment and Treatment of Asymptomatic Bacteriuria Necessary for Reducing the Risk of Postoperative Symptomatic Urinary Tract Infections After Urologic Surgical Procedures?. <i>Urology</i> , 2017, 99, 100-105.	1.0	26
106	The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 356-362.	1.9	31
107	Uncomplicated Bacterial Community-Acquired Urinary Tract Infection in Adults. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2017, 114, 866-873.	0.9	26
108	Urogenital Infection as a Risk Factor for Male Infertility. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2017, 114, 339-346.	0.9	122



#	ARTICLE	IF	CITATIONS
109	Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4. <i>Cell Communication and Signaling</i> , 2017, 15, 40.	6.5	17
110	Spectrum and antibiotic resistance of uropathogens between 2004 and 2015 in a tertiary care hospital in Hungary. <i>Journal of Medical Microbiology</i> , 2017, 66, 788-797.	1.8	30
111	Is overactive bladder in the female surgically curable by ligament repair?. <i>Central European Journal of Urology</i> , 2017, 70, 53-59.	0.3	23
112	Antibiotic Resistance and Novel Antibiotics for the Treatment of Urinary Tract Infections. <i>Urogenital Tract Infection</i> , 2016, 11, 43.	0.2	0
113	The Presentation, Diagnosis, and Treatment of Sexually Transmitted Infections. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2016, 113, 11-22.	0.9	73
114	Asymptomatic Bacteriuria in Clinical Urological Practice: Preoperative Control of Bacteriuria and Management of Recurrent UTI. <i>Pathogens</i> , 2016, 5, 4.	2.8	17
115	The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections. <i>Pathogens</i> , 2016, 5, 10.	2.8	62
116	Global epidemiology of urinary tract infections. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 73-79.	3.1	250
117	Grey Zones in the Field of Urinary Tract Infections. <i>European Urology Focus</i> , 2016, 2, 460-462.	3.1	10
118	The Global Prevalence of Infections in Urology (GPUi) Study: A Worldwide Surveillance Study in Urology Patients. <i>European Urology Focus</i> , 2016, 2, 345-347.	3.1	14
119	Management of the Urologic Sepsis Syndrome. <i>European Urology Supplements</i> , 2016, 15, 102-111.	0.1	5
120	TET enzymes are successively expressed during human spermatogenesis and their expression level is pivotal for male fertility. <i>Human Reproduction</i> , 2016, 31, 1411-1424.	0.9	38
121	Studying ceftazidime-avibactam in selected populations. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 621-623.	9.1	3
122	Urinary Tract Infections in Immunocompromised Patients with Diabetes, Chronic Kidney Disease, and Kidney Transplant. <i>European Urology Focus</i> , 2016, 2, 394-399.	3.1	31
123	The Acute Cystitis Symptom Score for Patient-Reported Outcome Assessment. <i>Urologia Internationalis</i> , 2016, 97, 402-409.	1.3	25
124	Reply to Dino PapeÅ, Ana JeronÄ's Letter to the Editor re: Giuseppe Magistro, Florian M.E. Wagenlehner, Magnus Grabe, Wolfgang Weidner, Christian G. Stief, J. Curtis Nickel. Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. <i>Eur Urol</i> 2016;69:286â€97. <i>European Urology</i> , 2016, 70, e166-e167.	1.9	2
125	Modern diagnostic methods for urinary tract infections. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 1047-1063.	4.4	25
126	Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 959-966.	3.3	5



#	ARTICLE	IF	CITATIONS
127	Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. <i>Clinical Infectious Diseases</i> , 2016, 63, 754-762.	5.8	281
128	Re: Comparative Effectiveness of Targeted vs Empirical Antibiotic Prophylaxis to Prevent Sepsis from Transrectal Prostate Biopsy: A Retrospective Analysis. <i>Journal of Urology</i> , 2016, 195, 224-225.	0.4	0
129	Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPU) study 2003-2013. <i>World Journal of Urology</i> , 2016, 34, 1193-1200.	2.2	70
130	Urinary Concentrations and Antibacterial Activity of BAL30072, a Novel Siderophore Monosulfactam, against Uropathogens after Intravenous Administration in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3309-3315.	3.2	10
131	Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. <i>European Urology</i> , 2016, 69, 286-297.	1.9	195
132	Ceftolozane-tazobactam versus levofloxacin in urinary tract infection - Authors' reply. <i>Lancet</i> , The, 2015, 386, 1242.	13.7	6
133	Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 658-666.	1.8	49
134	Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). <i>Lancet</i> , The, 2015, 385, 1949-1956.	13.7	318
135	A Randomized, Double-Blind, Parallel-Group, Multicenter Clinical Study of <i>Escherichia coli</i> -Lyophilized Lysate for the Prophylaxis of Recurrent Uncomplicated Urinary Tract Infections. <i>Urologia Internationalis</i> , 2015, 95, 167-176.	1.3	23
136	Editorial Comment from Dr Wagenlehner to Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: A database analysis in England. <i>International Journal of Urology</i> , 2015, 22, 186-186.	1.0	3
137	Treatment of Asymptomatic Bacteriuria Might Be Harmful. <i>Clinical Infectious Diseases</i> , 2015, 61, civ698.	5.8	8
138	Acute Epididymitis Revisited: Impact of Molecular Diagnostics on Etiology and Contemporary Guideline Recommendations. <i>European Urology</i> , 2015, 68, 428-435.	1.9	97
139	Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. <i>World Journal of Urology</i> , 2014, 32, 791-801.	2.2	71
140	Development and validation of a nomogram predicting recurrence risk in women with symptomatic urinary tract infection. <i>International Journal of Urology</i> , 2014, 21, 929-934.	1.0	25
141	Urinary tract infections and bacterial prostatitis in men. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 97-101.	3.1	50
142	New Self-Reporting Questionnaire to Assess Urinary Tract Infections and Differential Diagnosis: Acute Cystitis Symptom Score. <i>Urologia Internationalis</i> , 2014, 92, 230-236.	1.3	49
143	Urinary Concentrations and Antibacterial Activities of Nitroxoline at 250 Milligrams versus Trimethoprim at 200 Milligrams against Uropathogens in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 713-721.	3.2	47
144	Reducing infection rates after prostate biopsy. <i>Nature Reviews Urology</i> , 2014, 11, 80-86.	3.8	55

#	ARTICLE	IF	CITATIONS
145	Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one-year prospective, double-blind, placebo-controlled study. <i>World Journal of Urology</i> , 2014, 32, 1595-1603.	2.2	15
146	Healthcare-associated urinary tract infections in hospitalized urological patients—a global perspective: results from the GPIU studies 2003–2010. <i>World Journal of Urology</i> , 2014, 32, 1587-1594.	2.2	77
147	Acute epididymitis induces alterations in sperm protein composition. <i>Fertility and Sterility</i> , 2014, 101, 1609-1617.e5.	1.0	31
148	Re: Procalcitonin as a Diagnostic Marker for Sepsis: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2014, 66, 178.	1.9	4
149	Clinical presentation, risk factors and use of antibiotics in urinary tract infections. <i>Surgery</i> , 2014, 32, 297-303.	0.3	0
150	Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 1032-1038.	1.8	25
151	Antibiotic Prophylaxis in Urology Departments, 2005–2010. <i>European Urology</i> , 2013, 63, 386-394.	1.9	65
152	National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) Symptom Evaluation in Multinational Cohorts of Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. <i>European Urology</i> , 2013, 63, 953-959.	1.9	108
153	Reply from Authors re: Riccardo Bartoletti, Tommaso Cai. Prostate Biopsies Should Be Performed According to a Standard of Care. <i>Eur Urol</i> 2013;63:528–9. <i>European Urology</i> , 2013, 63, 529-530.	1.9	0
154	Infective Complications After Prostate Biopsy: Outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, A Prospective Multinational Multicentre Prostate Biopsy Study. <i>European Urology</i> , 2013, 63, 521-527.	1.9	280
155	Bacterial prostatitis. <i>World Journal of Urology</i> , 2013, 31, 711-716.	2.2	45
156	Some thoughts on the effect of non-linearity on innovation in urological surgery. <i>Central European Journal of Urology</i> , 2013, 66, 121-5.	0.3	1
157	Update on biofilm infections in the urinary tract. <i>World Journal of Urology</i> , 2012, 30, 51-57.	2.2	128
158	Pollen Extract for Chronic Prostatitis—Chronic Pelvic Pain Syndrome. <i>Urologic Clinics of North America</i> , 2011, 38, 285-292.	1.8	16
159	Antimicrobials in urogenital infections. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 3-10.	2.5	50
160	Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 64-70.	2.5	158
161	Uncomplicated Urinary Tract Infections. <i>Deutsches Arzteblatt International</i> , 2011, 108, 415-23.	0.9	77
162	Urodynamic Impact of Acute Urinary Retention in Patients with Benign Prostatic Hyperplasia: A 2-Year Follow-Up after Transurethral Resection of the Prostate. <i>Urologia Internationalis</i> , 2011, 86, 73-79.	1.3	5

#	ARTICLE	IF	CITATIONS
163	Urinary Pharmacokinetics and Bactericidal Activity of Finafloxacin (200 and 800 mg) in Healthy Volunteers Receiving a Single Oral Dose. <i>Chemotherapy</i> , 2011, 57, 97-107.	1.6	19
164	Emerging drugs for bacterial urinary tract infections. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 375-397.	2.4	13
165	Use of the UPOINT Chronic Prostatitis/Chronic Pelvic Pain Syndrome Classification in European Patient Cohorts: Sexual Function Domain Improves Correlations. <i>Journal of Urology</i> , 2010, 184, 2339-2345.	0.4	105
166	Urinary Bactericidal Activity of Doripenem versus That of Levofloxacin in Patients with Complicated Urinary Tract Infections or Pyelonephritis. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1567-1573.	3.2	35
167	Are Antisperm Antibodies Really Associated with Proven Chronic Inflammatory and Infectious Diseases of the Male Reproductive Tract?. <i>European Urology</i> , 2009, 56, 708-715.	1.9	46
168	A Pollen Extract (Cernilton) in Patients with Inflammatory Chronic Prostatitisâ€“Chronic Pelvic Pain Syndrome: A Multicentre, Randomised, Prospective, Double-Blind, Placebo-Controlled Phase 3 Study. <i>European Urology</i> , 2009, 56, 544-551.	1.9	146
169	An update on uncomplicated urinary tract infections in women. <i>Current Opinion in Urology</i> , 2009, 19, 368-374.	1.8	61
170	No benefit of $\alpha$ -blockers for chronic prostatitis. <i>Nature Reviews Urology</i> , 2009, 6, 183-184.	3.8	5
171	Therapy for prostatitis, with emphasis on bacterial prostatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1667-1674.	1.8	34
172	Pharmacokinetic Characteristics of Antimicrobials and Optimal Treatment of Urosepsis. <i>Clinical Pharmacokinetics</i> , 2007, 46, 291-305.	3.5	37
173	The role of inflammation and infection in the pathogenesis of prostate carcinoma. <i>BJU International</i> , 2007, 100, 733-737.	2.5	69
174	Asymptomatic Bacteriuria in Elderly Patients. <i>Drugs and Aging</i> , 2005, 22, 801-807.	2.7	34
175	Hospital-acquired urinary tract infections. <i>Journal of Hospital Infection</i> , 2000, 46, 171-181.	2.9	38